82 results about "Amphomycin" patented technology

The invention discloses a macrophage-polymer lipid nanoparticle composite drug delivery system, a preparation method thereof and application of the macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance. According to the drug delivery system, alpha-linolenic acid (ALA), high molecular weight chitosan oligosaccharide (HCOS) and amphotericin B (AmB) are used as raw materials to construct nanoparticles AmB-PLHNs, the nanoparticles are loaded in macrophages through the phagocytosis of the macrophages, and the AmB-PLHNs (at) M1 is constructed. AmB is a common medicine for clinically treating Cn infection, but has the problems of toxic and side effects on kidney and incapability of being transferred into the center. The AmB-PLHNs (at) M1 carries AmB-PLHNs to be transferred into the brain according to the blood-brain barrier penetrating characteristic of M1 type macrophages, and the brain entering efficiency of the medicine is improved. By combining the phagocytosis of macrophages on cryptococcus, the inflammation immune regulation function of the macrophages and the bacteriostatic action of the drug-loaded nanoparticles, the drug-loaded nano-particles are used for treating Cn central infection, and the toxic and side effects of AmB are reduced.

Disclosed are compositions comprising a lipid polymer excipient and AmB or an AmB derivative. The lipid polymer excipient can form micelles when formulated with AmB or the AmB derivative and can solubilize and stabilize the drug. Also disclosed are methods of treating a fungal infection using the compositions.

A hydrogel composition for intranasal delivery of an antifungal (amphotericin B) at an infection site, specifically the nasal mucosa and upper respiratory tract.

Compositions comprising a lipid polymer excipient and an AmB or an AmB derivative are disclosed. The lipid polymer excipient can form micelles when formulated with AmB or an AmB derivative, and can solubilize and stabilize the drug. Also disclosed are methods of treating a fungal infection comprising administering to a subject in need thereof a therapeutically effective amount of the composition.

The invention discloses an amplification culture solution of TILs cells and a culture method thereof. The amplification culture solution comprises a complete culture medium, and an anti-BTLA antibody with the final concentration of 0.1-10 [mu] g / mL, penicillin with the final concentration of 50-500 [mu] g / mL, streptomycin with the final concentration of 50-500 [mu] g / mL, gentamicin with the final concentration of 10-100 [mu] g / mL and amphotericin with the final concentration of 1-50 [mu] g / mL are added into the complete culture medium. The anti-BTLA antibody component in the culture solution can relieve inhibition of BTLA on T cells by blocking combination of BTLA and a ligand HVEM of BTLA, so that the anti-tumor capability of TILs is enhanced; meanwhile, after the BTLA is combined with the ligand HVEM, T cell activation and proliferation can be inhibited, and rapid proliferation of TILs is promoted; the irradiation PBMC added in the TILs cell culture process can provide an activation signal for the TILs and drive rapid proliferation of the TILs cells.

Provided are an amphotericin B amide derivative and a use thereof. The amphotericin B amide derivative is as shown in formula (I). The compound has good antifungal activity, is effective against various fungi, has good water solubility, is adapted to be developed into an injection dosage form, has excellent metabolic stability in animals (such as mice, rats, dogs, and monkeys), has a long half-life period, can effectively reduce the frequency of administration, has weak inhibition on CYP enzymes, and has a low risk of drug interaction.

The invention provides an amphotericin B amide derivative and application thereof. The amphotericin B amide derivative is shown as a formula (I), has good antifungal activity, is effective to various fungi, has good water solubility, is suitable for being developed into injections, has excellent metabolic stability in animal bodies (such as mice, rats, dogs and monkeys), is long in half-life period, can effectively reduce the administration frequency, is weak in CYP enzyme inhibition, and can be used for preparing the antifungal drugs. The drug interaction risk is low.

Disclosed are pharmaceutical compositions, comprising: (i) amphotericin B or a pharmaceutically acceptable salt or hydrate thereof; (ii) cholesterol; (iii) phospholipids, comprising hydrogenated soy phosphatidylcholine and distearoylphosphatidylglycerol; and (iv) calcium chloride (CaCl2)). Also disclosed are methods of using the pharmaceutical compositions for treating a disease or disorder (e.g., cystic fibrosis), increasing the pH of airway surface liquid, increasing bicarbonate secretion into airway surface liquid, and increasing a subject's forced expiratory volume in one second.

The invention belongs to the technical field of biological medicines, and in particular relates to an application of hyssopus rigidus var. Cupidus essential oil in preparation of an antibiotic antibacterial sensitizer and / or preparation of an antibiotic combined medicine, and further relates to an application of the hyssopus rigidus var. Cupidus essential oil in preparation of the antibiotic antibacterial sensitizer and / or the antibiotic combined medicine. It is found that the hyssop officinalis essential oil can enhance the antibacterial sensitivity of various antibiotics including fluconazole and amphotericin B, the hyssop officinalis essential oil and the antibiotics are combined for use, the synergistic antibacterial activity is achieved, and the better antibacterial effect is achieved while the dosage of the antibiotics is reduced; important technical support is provided for improving the current situation of drug resistance of fungi.

The present invention provides semisynthetic derivatives of amphotericin B, their preparation methods, and uses. Specifically, the present invention discloses compounds having a structure as shown in Formula V, as well as water-soluble salts and complexes, pharmaceutical compositions, and plant and body therapeutic products containing the derivatives, and their use as antifungal antibiotics. The present invention also discloses methods for preparing the aforementioned compounds. #imgabs0#

A composition comprising a lipid polymer excipient and AmB or an AmB derivative is disclosed. The lipid polymer excipient can form micelles when formulated with AmB or an AmB derivative, solubilizing and stabilizing the drug. Also disclosed is a method of treating fungal infections using this composition.

The invention relates to a process for obtaining an amphotericin B (AmB) formulation in liposomes containing dicetyl phosphate (DCP), based on incorporation of the drug into the membrane of preformed liposomes, combining the effects of pH on the solubility of amphotericin B and of temperature on the insertion of the drug into the liposome membrane. The technology also relates to use of the process and of the formulation for the manufacture of medicaments for the treatment of leishmaniasis and sporotrichosis, for oral or topical administration.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

The invention discloses a nano-robot based on tear driving, a preparation method of the nano-robot and application of the nano-robot in eye drops. The preparation method comprises the following steps: step 1, loading ophthalmic disease treatment drugs such as amphotericin B, voriconazole and natamycin into nano-particles such as polylactic acid-glycolic acid copolymer, chitosan and sodium alginate; 2, coupling urease on the surfaces of the nano-particles to obtain a nano-robot with autonomous movement ability; step 3, performing morphology characterization on the obtained nanometer robot driven by the tear liquid; and step 4, dispersing the prepared tear-driven nano-robot in a buffer solution to prepare the eye drops. The tear-driven nano-robot can utilize urea in tears as fuel to generate cluster motion on the cornea surface, so that the retention time is remarkably prolonged, the drug retention amount is increased, and the treatment effect is improved. The nano-robot eye drops based on tear driving have biocompatibility and treatment safety, and have wide application prospects in the field of ophthalmic local administration.

Disclosed is a simplified, readily scalable series of individual methods that collectively constitute a method for the synthesis of C2'epiAmB, an efficacious and reduced-toxicity derivative of amphotericin B (AmB), beginning from AmB. Also provided are various compounds corresponding to intermediates in accordance with the series of methods.

The invention discloses a method for detecting the total number of mould and saccharomycetes of amphotericin B. The method comprises the following steps: (1) preparing mould and / or saccharomycetes to be detected into a bacterium suspension; (2) adding a sulfydryl-containing neutralizer into the SDA culture medium to obtain a neutralizer-containing SDA culture medium; (3) weighing an amphotericin B sample, and diluting the amphotericin B sample with a buffer solution to obtain a test solution; and (4) adding a test solution into the bacterial suspension, uniformly mixing, injecting into a neutralizer-containing SDA culture medium, culturing, and counting to obtain the total number of mould and / or saccharomycetes of amphotericin B. According to the method, a technology combining a dilution method and a neutralization method is adopted, a test sample is diluted, a sulfydryl-containing neutralizer is added into an SDA culture medium, amphotericin B molecules are effectively wrapped, and contact between the amphotericin B molecules and fungal microorganism cell membranes is reduced, so that the bacteriostatic activity of the amphotericin B molecules is eliminated, the inhibition effect of the amphotericin B on sensitive fungi is solved, the recovery rate is effectively increased, and the method is suitable for industrial production. And accurate microbial limit detection is realized.

The present application relates to the use of amphotericin B or its combination in the preparation of anti-tumor drugs. The present application first confirms that amphotericin B directly binds to Toll-like receptor 2 and activates the downstream signaling pathway as a Toll-like receptor 2 agonist, thereby enhancing the phagocytic ability of macrophages to tumor cells; it is first confirmed that amphotericin B combined with therapeutic antibodies can produce a synergistic anti-tumor effect, and the above synergistic effect is mainly due to the regulatory effect of amphotericin B on macrophage function, including enhancing Fc gamma receptor expression and polarizing macrophages to M1 direction, which provides a solid foundation for the clinical transformation of amphotericin B and is expected to provide new treatment options for cancer patients.

This invention discloses a highly stable amphotericin B liposome and its preparation method, belonging to the field of pharmaceutical formulation technology. This invention utilizes a methanol-water-chloroform ternary mixed solvent system to achieve complete molecular-level dissolution of the raw materials, eliminating the conventional drying process and directly hydrating and homogenizing. It also provides optimal formulation ratios and process parameters. The preparation method includes steps such as oil phase preparation, aqueous phase preparation, homogenization, incubation, cooling, filtration, volumetric filling, and lyophilization. This invention creatively proposes optimal formulation composition and process conditions, resulting in a product with high encapsulation efficiency, uniform particle size, and strong stability. Furthermore, the preparation process is simple and easily industrialized, solving the problems of complex preparation processes and poor stability of existing injectable amphotericin B liposomes, and possesses good clinical application value.

The invention relates to the field of liposome manufacturing, and discloses an amphotericin B liposome and a preparation method thereof, and the amphotericin B liposome comprises the following components in parts by mass: 1 part of amphotericin B, 5-10 parts of hydrogenated soybean phospholipid (HSPC), 2-4 parts of cholesterol, 1-3 parts of mPEG2000-DSPE, 0.5-1.5 parts of ceramide, 0.3-0.8 part of glycyrrhetinic acid, 0.2-0.5 part of hydroxyapatite nanoparticles (nHAP) and 8-15 parts of a freeze-drying protective agent. The glycyrrhetinic acid is added, and the specific targeting effect of the glycyrrhetinic acid is utilized, so that the in-vitro binding rate of fungal cells of the lipidosome is improved, the enrichment rate of the medicine at an infected part is further improved, and the core problem of renal toxicity caused by non-targeting distribution of a traditional preparation is effectively solved; the hydroxyapatite nanoparticles adsorb medicine molecules to form a medicine-nHAP compound, and the medicine crystallization rate is greatly reduced by combining the synergistic anti-crystallization effect of the freeze-drying protective agent.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

This invention discloses a method for determining the encapsulation efficiency of amphotericin B liposomes for injection, comprising the following steps: separating the amphotericin B liposome solution for injection using solid-phase extraction adsorption to obtain an encapsulated drug solution and a free drug solution; and determining the drug mass concentration C in the encapsulated drug solution using HPLC. 包封 Drug mass concentration C in free drug solution 游离 And the total drug concentration C in the amphotericin B liposome solution before separation 总 The encapsulation efficiency and recovery rate of amphotericin B liposomes were calculated. This invention utilizes a macroporous copolymer of divinylbenzene and N-vinylpyrrolidone as the adsorbent in a solid-phase extraction adsorption method. Its macroporous structure provides ample adsorption sites while avoiding physical compression and damage to the liposome vesicles. This method achieves the separation of free amphotericin B liposomes from the encapsulated drug, exhibiting good reproducibility, high accuracy, simple operation, and high recovery rate.

The invention discloses a screening culture medium and a preparation method and application thereof, the screening culture medium comprises a basic culture medium and additives, and the additives comprise amphotericin B, vancomycin, ox bile salt, sodium deoxycholate and No.3 bile salt. According to the screening culture medium provided by the invention, a special infectious microbe inhibitor is added on the basis of a trisaccharide iron culture medium, so that most gram-negative enterobacter, staphylococcus aureus and part of fungi except salmonella enteritis subspecies and shigella cannot grow; the interference of the infectious microbes on the detection of the salmonella enteritis subspecies and the shigella is avoided, so that the fluorescent probe can be applied to the detection of the salmonella enteritis subspecies and the shigella in a clinical anus swab, and the sensitivity of color development is improved.

This invention belongs to the field of organoid culture technology, specifically relating to a highly efficient organoid anticontamination reagent. This highly efficient organoid anticontamination reagent is composed of Primocin, amphotericin B, and Y-27632. In the organoid culture medium system, the final concentration of Primocin is 20-70 μg / mL, the final concentration of amphotericin B is 0.1-1 μg / mL, and the final concentration of Y-27632 is 5-20 μM. The highly efficient organoid anticontamination reagent provided by this invention exhibits dual high-efficiency inhibition against both bacteria and fungi, has a broad anticontamination spectrum, and is not prone to inducing microbial resistance. Simultaneously, it can reduce cytotoxicity, and long-term use does not alter the expression of organoid-specific markers, thus maintaining differentiation function.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The present invention discloses a Vibrio vulnificus selective culture medium and a preparation method thereof. The culture medium comprises a basal culture medium and additives; the basal culture medium comprises peptone, beef extract powder, sodium chloride, potassium chloride, a long-chain alkyl sulfate anionic surfactant or nisin, D-cellobiose, an acid-base indicator, and agar; the additive is tellurite; and the solvent is water. When the basal culture medium contains nisin, the additives further comprise vancomycin, amphotericin B, and polymyxin E. The Vibrio vulnificus selective culture medium of the present invention has high growth selectivity, effectively inhibits the growth of Gram-positive bacteria, effectively inhibits fungal growth, and is sensitive and specific for detecting Vibrio vulnificus. Furthermore, the preparation method does not require autoclaving and avoids the inconvenience of preparing the high-content component, cellobiose, into a sterile additive prior to use, making it more convenient.

The invention provides a pharmaceutical composition of an amphotericin B derivative and application of the pharmaceutical composition. Specifically, the invention provides an injection taking the amphotericin B derivative or pharmaceutically acceptable salt thereof as an active ingredient, and the injection comprises liposome, injection and a cholesterol sodium sulfate compound preparation. The compound is expected to become a new generation of systemic fungal infection treatment medicine.

The present invention relates to a pharmacotrophic ophthalmic composition comprising resveratrol, advantageously in an amount greater than 20 mg, for administration to a subject receiving anti-VEGF therapy.

The invention provides an amphotericin B hydrazide derivative and application thereof. The amphotericin B hydrazide derivative is shown as a formula (I). The compound disclosed by the invention has an obvious inhibition effect on the growth of candida albicans, aspergillus fumigatus and aspergillus flavus. (I).